ValuEngine downgraded shares of Retrophin, Inc. (NASDAQ:RTRX) from a hold rating to a sell rating in a report issued on Monday morning.

A number of other brokerages also recently issued reports on RTRX. BidaskClub upgraded shares of Retrophin from a buy rating to a strong-buy rating in a report on Thursday, August 24th. BMO Capital Markets reiterated a buy rating and issued a $44.00 price target on shares of Retrophin in a report on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Retrophin from a hold rating to a strong sell rating in a report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Retrophin currently has an average rating of Buy and an average target price of $36.00.

Retrophin (RTRX) opened at $21.42 on Monday. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15. Retrophin has a twelve month low of $15.55 and a twelve month high of $26.44.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.21). The company had revenue of $40.34 million during the quarter, compared to analysts’ expectations of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The business’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) EPS. analysts expect that Retrophin will post -1.25 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/retrophin-inc-rtrx-stock-rating-lowered-by-valuengine/1723832.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its stake in Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 146 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Retrophin by 1.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after acquiring an additional 290 shares during the last quarter. Legal & General Group Plc grew its stake in Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 355 shares during the last quarter. AJO LP grew its stake in Retrophin by 1.9% in the 2nd quarter. AJO LP now owns 59,681 shares of the biopharmaceutical company’s stock valued at $1,157,000 after acquiring an additional 1,094 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in Retrophin by 3.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after acquiring an additional 1,200 shares during the last quarter.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.